Descripción del título
The evaluation of surrogate...
The identification and use of surrogate endpoints, i.e., measures that can replace or supplement other endpoints in evaluations of experimental treatments or other interventions, is a general strategy that has stimulated both enthusiasm and scepticism. This book offers a balanced account on this controversial topic
Monografía
monografia Rebiun25855819 https://catalogo.rebiun.org/rebiun/record/Rebiun25855819 m o d cr |n||||||||| 041019s2005 nyua ob 001 0 eng c 2004059192 209818684 213887734 228148950 228148951 228396251 316866765 320966191 437183499 647551673 698450714 756418292 814404866 823139256 824172015 880016088 992099793 994849638 1005814255 1035649828 1044097869 1044131569 1044295008 1044312379 1056299798 1056327815 1056329685 1056423599 1058038010 1060696185 1060817338 1067025128 1077997105 1087351931 1097326933 1097330761 1102278497 1110738861 1110907773 1112518378 1125430177 1136285281 0387202773 alk. paper) 9780387202778 alk. paper) 0387270809 electronic bk.) 9780387270807 electronic bk.) 6610308292 9786610308293 128030829X 9781280308291 10.1007/b138566 doi AU@ 000042137167 AU@ 000048754264 DEBSZ 264334043 DEBSZ 442809409 DKDLA 820120-katalog:000661760 HEBIS 192014897 NLGGC 292351909 NZ1 12050027 978-0-387-20277-8 Springer http://www.springerlink.com COO eng pn COO N$T YDXCP GW5XE UAB CNTRU OCLCQ GBT TUU OCLCQ IDEBK YNG MHW E7B OCLCQ OCLCO EBLCP OCLCQ A7U OCLCQ NLGGC OCLCF OCLCQ DEBSZ OCLCQ LVT OCLCO Z5A LIP PIFBR OTZ OCLCQ ESU OCLCQ VT2 WY@ OCLCO OCLCA LUE OCLCO STF GILDS OCLCO CEF U3W OCLCQ AU@ OCLCO WYU OCLCO OCLCA ICG UWO YOU OCLCQ CANPU OCLCO W2U OCLCO AUD OCLCQ MERUC ZHM DCT ERF OCLCQ SFB OCLCA pcc R lcco MED 047000 bisacsh MBGR bicssc 610/.72/4 22 44.45 bcl The evaluation of surrogate endpoints Tomasz Burzykowski, Geert Molenberghs, Marc Buyse, editors New York Springer 2005 New York New York Springer 1 online resource (xxiii, 408 pages) illustrations 1 online resource (xxiii, 408 pages) Text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda Statistics for biology and health Includes bibliographical references (pages 367-399) and index Introduction -- Setting the Scene -- Regulatory Aspects in Using Surrogate Markers in Clinical Trials -- Notation and Motivating Studies -- The History of Surrogate Marker Validation -- Validation Using Single-Trial Data: Mixed Binary and Continuous Outcomes -- A Meta-Analytic Validation Framework for Contiuous Outcomes -- The Choice of Units -- Extensions of the Meta-Analytic Approach to Surrogate Endpoints -- Meta-Analytic Validation with Binary Outcomes -- Validation in the Case of Two Failure-Time Endpoints -- An Ordinal Surrogate for a Survival True Endpoint -- A Combination of Longitudinal and Survival Endpoints -- Repeated Measures and Surrogate Marker Validation -- Bayesian Evaluation of Surrogate Endpoints -- Surrogate Marker Validation in Mental Health -- The Evaluation of Surrogate Endpoints in Practice: Experience in HIV -- An Alternative Measure for Meta-Analytic Surrogate Marker Validation -- Discussion: Surrogate Endpoint Definition and Evaluation --The Promise and Peril of Surrogate End Points in Cancer Research The identification and use of surrogate endpoints, i.e., measures that can replace or supplement other endpoints in evaluations of experimental treatments or other interventions, is a general strategy that has stimulated both enthusiasm and scepticism. This book offers a balanced account on this controversial topic English Clinical trials Drugs- Testing Biomarkers Clinical Trials as Topic Drug Evaluation MEDICAL- Laboratory Medicine Clinical trials Drugs- Testing Electronic books Molenberghs, Geert Buyse, Marc E. Burzykowski, Tomasz Springer e-books Springer e-books Print version Evaluation of surrogate endpoints. New York : Springer, 2005 0387202773 (DLC) 2004059192 (OCoLC)56807737 Statistics for biology and health